XTL Biopharmaceuticals Sponsored ADR AI Stock Analysis
Want to see XTLB full AI Analyst Report?
XTL Biopharmaceuticals Sponsored ADR (XTLB) AI Stock Analysis
XTL Biopharmaceuticals Sponsored ADR
(NASDAQ:XTLB)
XTL Biopharmaceuticals Ltd. shows considerable financial difficulties with persistent losses and weak cash flow. The technical analysis aligns with a bearish outlook, while valuation metrics highlight an unattractive investment at present. Although the stock has seen a recent price surge, the absence of earnings call details makes future performance uncertain.
XTL Biopharmaceuticals Sponsored ADR (XTLB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.51M
- Dividend Yield
- ―
- Average Volume (3M)
- 8,875
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 1.14
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 10
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
XTL Biopharmaceuticals Sponsored ADR Business Overview & Revenue Model
Company Description
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting sys...
How the Company Makes Money
XTL Biopharmaceuticals generates revenue primarily through the development and commercialization of proprietary drug candidates targeting autoimmune diseases and cancer. The company may earn money from licensing agreements, milestone payments, and ro...
XTL Biopharmaceuticals Sponsored ADR Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XTLB, the sentiment is Negative. The current price of 1.60 is below the 20-day moving average (MA) of 1.76, below the 50-day MA of 2.04, and below the 200-day MA of 2.60, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 39.13 is Neutral, neither overbought nor oversold. The STOCH value of 19.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XTLB.
XTL Biopharmaceuticals Sponsored ADR Risk Analysis
XTL Biopharmaceuticals Sponsored ADR disclosed 38 risk factors in its most recent earnings report. XTL Biopharmaceuticals Sponsored ADR reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksXTL Biopharmaceuticals Sponsored ADR Peers Comparison
Overall Rating
PCSA55Neutral
XBIO46Neutral
ACXP45Neutral
ADXN44Neutral- XTLB39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PCSA | 55Neutral | $5.15M | -0.03 | -394.24% | ― | ― | 90.37% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| XBIO | 46Neutral | $3.89M | -1.05 | -58.96% | ― | 3.50% | 22.76% |
| ACXP | 45Neutral | $5.48M | -0.34 | -0.44% | ― | ― | 72.95% |
| ADXN | 44Neutral | $5.16M | -0.69 | -172.76% | ― | -45.76% | -3.77% |
| XTLB | 39Underperform | $7.25M | -0.54 | -269.02% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XTLB | XTL Biopharmaceuticals Ltd. Sponsored ADR | 1.60 | -2.04 | -56.04% | |
| PMCB | Pharmacyte Biotech, Inc. | 6.68 | -7.10 | -51.51% | |
| XBIO | Xenetic Biosciences, Inc. | 1.66 | -0.83 | -33.33% | |
| PCSA | Processa Pharmaceuticals, Inc. | 1.86 | -4.98 | -72.81% | |
| ADXN | Addex Therapeutics Ltd (ADR) | 4.06 | -4.34 | -51.67% | |
| ACXP | Acurx Pharmaceuticals Llc | 0.96 | -3.26 | -77.25% |
XTL Biopharmaceuticals Sponsored ADR Corporate Events
XTL Biopharmaceuticals Takes Major Impairment on The Social Proxy in First-Half 2025 Results
On December 30, 2025, XTL Biopharmaceuticals reported financial results for the six months ended June 30, 2025, highlighting a near-full write-down of its subsidiary The Social Proxy following a prolonged dispute with the unit’s former shareholders a...
XTL Biopharmaceuticals Faces Nasdaq Bid-Price Deficiency, Given Until June 2026 to Regain Compliance
On December 24, 2025, XTL Biopharmaceuticals announced it had received a Nasdaq notification, dated December 22, 2025, stating that the company’s American Depositary Shares had failed to meet the exchange’s minimum bid price requirement of $1 per sha...
XTL Biopharmaceuticals Faces Leadership Changes at Social Proxy Subsidiary
On December 11, 2025, XTL Biopharmaceuticals Ltd. announced the immediate resignation of Tal Klinger, CEO, and Roee Klinger, CTO, from Social Proxy Ltd., its wholly owned subsidiary. The company is currently assessing the management strategy for Soci...
XTL Biopharmaceuticals Announces CFO Transition Amid Strategic Appointments
On December 5, 2025, XTL Biopharmaceuticals announced the resignation of its Chief Financial Officer, Mr. Itay Weinstein, effective December 11, 2025. His departure was not due to any disagreements with the company. To fill the vacancy, the Board of...
XTL Biopharmaceuticals Announces Board Changes Following Resignation
On October 21, 2025, Doron Turjeman resigned from the Board of Directors of XTL Biopharmaceuticals Ltd. due to personal reasons, with no disagreements with the company. Subsequently, Noam Band, the CEO, was appointed to the board, potentially strengt...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2024